S&P 500   3,322.26 (-1.04%)
DOW   27,755.47 (-0.53%)
QQQ   266.39 (-1.45%)
AAPL   107.43 (-2.64%)
MSFT   198.83 (-2.01%)
FB   253.25 (-0.62%)
GOOGL   1,454.17 (-2.21%)
AMZN   2,949.35 (-1.97%)
NVDA   487.62 (-2.19%)
TSLA   440.00 (+3.91%)
BABA   274.00 (-0.62%)
CGC   16.49 (+0.55%)
GE   7.00 (-0.71%)
MU   50.99 (+0.02%)
AMD   74.92 (-2.13%)
T   29.05 (-0.07%)
F   7.29 (+0.14%)
ACB   6.62 (-3.92%)
GILD   64.70 (-0.52%)
NFLX   466.00 (-0.89%)
DIS   129.83 (-0.30%)
BAC   25.50 (+0.59%)
BA   164.62 (-1.74%)
S&P 500   3,322.26 (-1.04%)
DOW   27,755.47 (-0.53%)
QQQ   266.39 (-1.45%)
AAPL   107.43 (-2.64%)
MSFT   198.83 (-2.01%)
FB   253.25 (-0.62%)
GOOGL   1,454.17 (-2.21%)
AMZN   2,949.35 (-1.97%)
NVDA   487.62 (-2.19%)
TSLA   440.00 (+3.91%)
BABA   274.00 (-0.62%)
CGC   16.49 (+0.55%)
GE   7.00 (-0.71%)
MU   50.99 (+0.02%)
AMD   74.92 (-2.13%)
T   29.05 (-0.07%)
F   7.29 (+0.14%)
ACB   6.62 (-3.92%)
GILD   64.70 (-0.52%)
NFLX   466.00 (-0.89%)
DIS   129.83 (-0.30%)
BAC   25.50 (+0.59%)
BA   164.62 (-1.74%)
S&P 500   3,322.26 (-1.04%)
DOW   27,755.47 (-0.53%)
QQQ   266.39 (-1.45%)
AAPL   107.43 (-2.64%)
MSFT   198.83 (-2.01%)
FB   253.25 (-0.62%)
GOOGL   1,454.17 (-2.21%)
AMZN   2,949.35 (-1.97%)
NVDA   487.62 (-2.19%)
TSLA   440.00 (+3.91%)
BABA   274.00 (-0.62%)
CGC   16.49 (+0.55%)
GE   7.00 (-0.71%)
MU   50.99 (+0.02%)
AMD   74.92 (-2.13%)
T   29.05 (-0.07%)
F   7.29 (+0.14%)
ACB   6.62 (-3.92%)
GILD   64.70 (-0.52%)
NFLX   466.00 (-0.89%)
DIS   129.83 (-0.30%)
BAC   25.50 (+0.59%)
BA   164.62 (-1.74%)
S&P 500   3,322.26 (-1.04%)
DOW   27,755.47 (-0.53%)
QQQ   266.39 (-1.45%)
AAPL   107.43 (-2.64%)
MSFT   198.83 (-2.01%)
FB   253.25 (-0.62%)
GOOGL   1,454.17 (-2.21%)
AMZN   2,949.35 (-1.97%)
NVDA   487.62 (-2.19%)
TSLA   440.00 (+3.91%)
BABA   274.00 (-0.62%)
CGC   16.49 (+0.55%)
GE   7.00 (-0.71%)
MU   50.99 (+0.02%)
AMD   74.92 (-2.13%)
T   29.05 (-0.07%)
F   7.29 (+0.14%)
ACB   6.62 (-3.92%)
GILD   64.70 (-0.52%)
NFLX   466.00 (-0.89%)
DIS   129.83 (-0.30%)
BAC   25.50 (+0.59%)
BA   164.62 (-1.74%)
Log in
NASDAQ:MBII

Marrone Bio Innovations Stock Forecast, Price & News

$1.19
-0.02 (-1.65 %)
(As of 09/18/2020 12:14 PM ET)
Add
Compare
Today's Range
$1.19
Now: $1.19
$1.21
50-Day Range
$1.10
MA: $1.27
$1.45
52-Week Range
$0.61
Now: $1.19
$1.65
Volume1,736 shs
Average Volume199,600 shs
Market Capitalization$178.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Stargus/Amplitude, a biofungicide to control plant diseases, such as Sclerotinia white molds, gray mold/bunch rot, and downy mildews; Haven, a plant health product that is applied to the leaves of plants to reduce sun stress; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.
Read More
Marrone Bio Innovations logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
Current SymbolNASDAQ:MBII
CUSIPN/A
Phone530-750-2800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.37 million
Book Value$0.18 per share

Profitability

Net Income$-37,170,000.00
Net Margins-102.44%

Miscellaneous

Employees113
Market Cap$178.22 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$1.19
-0.02 (-1.65 %)
(As of 09/18/2020 12:14 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MBII News and Ratings via Email

Sign-up to receive the latest news and ratings for MBII and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

How has Marrone Bio Innovations' stock been impacted by COVID-19 (Coronavirus)?

Marrone Bio Innovations' stock was trading at $0.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MBII shares have increased by 38.4% and is now trading at $1.19.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Marrone Bio Innovations?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Marrone Bio Innovations
.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Marrone Bio Innovations
.

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations Inc (NASDAQ:MBII) posted its quarterly earnings data on Monday, August, 10th. The basic materials company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The basic materials company earned $12.18 million during the quarter, compared to the consensus estimate of $10.62 million. Marrone Bio Innovations had a negative net margin of 102.44% and a negative return on equity of 89.93%.
View Marrone Bio Innovations' earnings history
.

What price target have analysts set for MBII?

4 Wall Street analysts have issued twelve-month target prices for Marrone Bio Innovations' stock. Their forecasts range from $1.65 to $2.50. On average, they expect Marrone Bio Innovations' share price to reach $1.93 in the next twelve months. This suggests a possible upside of 61.8% from the stock's current price.
View analysts' price targets for Marrone Bio Innovations
.

Are investors shorting Marrone Bio Innovations?

Marrone Bio Innovations saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,110,000 shares, a drop of 11.3% from the August 15th total of 2,380,000 shares. Based on an average daily trading volume, of 173,900 shares, the days-to-cover ratio is presently 12.1 days. Approximately 2.3% of the company's shares are sold short.
View Marrone Bio Innovations' Short Interest
.

Who are some of Marrone Bio Innovations' key competitors?

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Matinas BioPharma (MTNB), Ekso Bionics (EKSO), KushCo (KSHB), 22nd Century Group (XXII), BioNano Genomics (BNGO), Enerplus (ERF), OrganiGram (OGI), AEterna Zentaris (AEZS), ADMA Biologics (ADMA) and DHT (DHT).

Who are Marrone Bio Innovations' key executives?

Marrone Bio Innovations' management team includes the following people:
  • Dr. Pamela G. Marrone, Founder, CEO & Director (Age 62)
  • Mr. James B. Boyd, Pres & CFO (Age 66)
  • Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 72)
  • Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 64)
  • Andre Trepanier, Director of Marketing

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

Who are Marrone Bio Innovations' major shareholders?

Marrone Bio Innovations' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nuveen Asset Management LLC (0.12%), Charles Schwab Investment Management Inc. (0.12%), Bank of New York Mellon Corp (0.10%), American International Group Inc. (0.03%) and ICM Asset Management Inc. WA (0.01%).
View institutional ownership trends for Marrone Bio Innovations
.

Which institutional investors are selling Marrone Bio Innovations stock?

MBII stock was sold by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA.
View insider buying and selling activity for Marrone Bio Innovations
.

Which institutional investors are buying Marrone Bio Innovations stock?

MBII stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, and American International Group Inc..
View insider buying and selling activity for Marrone Bio Innovations
.

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $1.19.

How big of a company is Marrone Bio Innovations?

Marrone Bio Innovations has a market capitalization of $178.22 million and generates $29.37 million in revenue each year. The basic materials company earns $-37,170,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Marrone Bio Innovations employs 113 workers across the globe.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is www.marronebioinnovations.com.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.